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Abstract
Interferon (IFN) is an effective therapy for multiple disorders. An infrequently reported 
side effect is thrombotic microangiopathy (TMA): thrombotic thrombocytopenic purpura 
(TTP) and hemolytic uremic syndrome (HUS). We published the first comprehensive 
review analyzing this association with the following observations: (1) there was a higher 
incidence of IFN-induced TMA in myeloproliferative disorders (chronic myelogenous 
leukemia (CML)) than that in nonmalignant disorders (multiple sclerosis (MS), chronic 
hepatitis C virus infection (HCV)); (2) mean age at diagnosis was 47 years; (3) there was 
rare association with hairy cell leukemia (HCL), Sezary syndrome (one case each) and 
no cases reported for polycythemia vera (PV); (4) sex distribution was balanced (excep-
tion of higher prevalence in females for MS); (5) TMA was insidious in onset with long 
incubation periods (average treatment duration 40.4 months); (6) comparative analysis 
of mean time (months) to onset of TMA ensuing cumulative IFN exposure was: MS 68.6 
vs. CML 35.5 vs. HCV 30.4; (7) confirmed TTP (low ADAMTS 13 levels) was associated 
with the presence of an inhibitor; (8) outcome analysis revealed complete remission in 27 
(40%), persistent chronic kidney disease in 28 (42%) and fatality in 12 patients (18%); (9) 
corticosteroids, plasma exchange (PEX) and rituximab are effective therapies.
Keywords: thrombocytopenia, interferon, thrombotic microangiopathy (TMA), 
thrombotic thrombocytopenia purpura (TTP), myeloproliferative disorder, HCV
1. Introduction
Thrombocytopenia is a common side effect of IFN treatment. TMA is a distinct clinical entity 
with potentially fatal consequences without precise and expeditious intervention. Classic 
clinical presentation includes a triad of anemia, thrombocytopenia, and evidence of micro-
angiopathic hemolysis on the peripheral blood smear. The quintessential pathologic feature 
is the development of microvascular thrombi affecting small or larger vessels with variable 
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organ involvement. TMA, including TTP, is associated with a broad spectrum of conditions 
such as hemolytic uremic syndrome (HUS), disseminated intravascular coagulation (DIC), 
malignant hypertension, infections, autoimmune disorders and drugs. Irrespective of etiol-
ogy, endothelial damage is the fundamental process and is instrumental in the generation of 
intravascular microthrombi [1]. Furthermore, TTP is characterized by decreased ADAMTS-13 
levels, with most patients having severe deficiency (<10%). There was no prior precedent of a 
comprehensive review exploring IFN-associated TMA. We performed a PubMed search of all 
articles published between January 1993 and July 2016, focusing on interferon-induced TMA 
cross-referenced with the following terms: thrombotic thrombocytopenic purpura (TTP), IFN 
and thrombocytopenia, thrombotic microangiopathies, ADAMTS-13, autoimmune disease 
and IFN, interferon and hepatitis C, IFN and CML, IFN and multiple myeloma, IFN and renal 
cell cancer, IFN and polycythemia vera, IFN and lymphoma. Our analysis of this data was 
published in an exclusive review [2] with results outlined in the following sections.
2. Results
2.1. Age
Majority of patients were between 40 and 60 years of age. Mean ± SE was 47 (95% CI, 44–50). 
There was no correlation between age and duration of interferon treatment (Figure 1). For 
comparison of older (≥60 years) to younger (<60 years) patients with regard to the duration of 
IFN treatment, Mann Whitney U test was used; median and interquartile range (in months) 
Figure 1. Correlation of age to duration of interferon (IFN) treatment before developing TMA. Sixty-eight patients 
including 29 CML, 20 MS, 17 Hepatitis C, 1 hairy cell leukemia, and 1 Sezary syndrome were studied. Correlation 
analysis using nonparametric Spearman’s method was used to correlate age and duration of treatment (months). No 
significant correlation between age and duration of IFN usage was found.
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were (28, 5.5–46) and (23.50, 5–60) for older and younger age groups, respectively. Results 
were not statistically significant (Figure 2).
2.2. Sex
On cumulative data review, for the cases where information was available, sex distribution 
was balanced (30 male and 33 female patients). In subgroup analysis, patients with MS treated 
with IFNβ had a female predominance (12 out of 16; 75%). This may, however, just be reflec-
tive of higher prevalence of MS in women.
2.3. Associated clinical conditions
An aggregate of 68 cases reported from January 1993 to July 2016 was reviewed. The chrono-
logic distribution of cases of IFN-induced TMA based on underlying diagnosis is shown 
in Figure 3. Incidence was highest in patients with CML followed by MS and HCV (29, 
20 and 17, respectively) [3–44]. One case each was reported in patients with hairy cell leu-
kemia (HCL) and Sezary syndrome [45, 46]. There have been no reports in patients with 
CML in the last 10 years correlating with the change in standard of care for the treatment 
of CML with tyrosine kinase inhibitors. There was no apparent difference in age distribu-
tion based on diagnosis. The cumulative duration of IFN exposure was highest in patients 
with MS treated with IFN β when compared to CML or HCV treated with IFN α: mean 
(months) ± SE: MS 68.6 (95% CI, 45.85–91.4), CML 35 (95% CI, 25.3–45.7) and HCV 12 (95% 
CI, 0.14–23.94). This was statistically significant (Figure 4) and is probably due to the differ-
ence in interferon type or different disease entity (IFNβ in MS vs. IFNα in CML and HCV). 
Figure 2. Comparison between older age (≥60) with younger age (<60) in relation to the duration of IFN usage. In order 
to compare older (≥60 years) to younger (<60 years) patients with regard to the duration of interferon treatment, Mann 
Whitney U test was used; median and interquartile range (in months) were (28, 5.5–46) and (23.50, 5–60) for older and 
younger age groups, respectively. No statistical significance was found.
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Figure 3. Incidence of reported cases of thrombotic microangiopathy by year and diagnosis: Results of incidence data 
analysis from the first reported case of IFN-induced TMA in 1993 to July 2016.
Figure 4. Comparison of cumulative IFN dose exposure prior to the onset of TMA in patients with CML, Hepatitis C, 
MS. Patients with MS treated with IFNβ showed longest duration of treatment exposure prior to the onset of TMA in 
comparison with patients with CML and hepatitis C treated with IFNα. Data were statistically significant.
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Predominant clinical  presentation was neurologic dysfunction, anemia, thrombocytopenia, 
and renal  insufficiency. Platelet counts were analyzed for 50 patients where complete blood 
count (CBC) data were available. Sixteen patients were diagnosed with TTP based on clinical 
presentation, low ADAMTS13 level, renal biopsy or other evidence of TMA and the remain-
ing as HUS, TTP-HUS or TMA. We grouped the latter for the purpose of our analysis as TMA 
unspecified. It appears that all patients with TTP presented with moderate-to-severe throm-
bocytopenia. In the group TMA unspecified, this was not a consistent finding (Figure 5). A 
significant number of patients were diagnosed as having TMA based on characteristic renal 
biopsy findings of microangiopathy. There were no other clearly discernible features that set 
these subgroups of patients apart.
2.4. Treatment and outcome
In our review of the 63 patients with available treatment data, 35 (56%) were treated with 
plasma exchange (PEX) with or without steroids, 12 (19%) were treated with steroids with or 
without plasma infusion, and 16 (25%) were treated by other means including IFN discon-
tinuation or dose reduction, antihypertensive treatment, rituximab and hemodialysis. Of the 
67 patients with available outcome data, 27 patients (40%) had complete response, 28 (42%) 
developed persistent CKD and 12 (18%) had a fatal outcome (Figure 6).
Figure 5. Platelet count trend at the time of diagnosis of TTP and TMA unspecified. Out of the 50 patients with available 
CBC data, 16 were diagnosed as TTP and rest as HUS, TTP-HUS or TMA. Data from the latter group of patients were 
pooled for the purpose of analysis as TMA unspecified. Patients with TTP presented consistently with moderate-to-
severe thrombocytopenia, whereas there were wide fluctuations in platelet counts in patients with TMA unspecified.
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2.5. Role of ADAMTS-13 inhibitor
There were eight cases of TTP where low ADAMTS 13 level was demonstrated, six of these 
also had ADAMTS 13 inhibitor. Notably, all patients with ADAMTS 13 inhibitor responded 
to PEX, steroids, and, in resistant cases, rituximab and vincristine. These results imply that 
IFN-induced TTP is probably an immune-mediated phenomenon with immune suppression 
being a key therapeutic intervention. ADAMTS13 levels were not available for all other cases 
making clear distinction between TTP and HUS difficult. We therefore analyzed results under 
the broader umbrella of TMA. In this context, we used a composite term TTP-HUS for clinical 
description.
3. Discussion
IFNs are a family of natural cytokines that interfere with viral replication, cell proliferation 
and immune regulation. Endogenous interferon production constitutes the initial nonspe-
cific immune response against viral infections before specific host immune repertoire takes 
over. There are two major types of endogenous interferons: type 1 (IFNα—produced by 
leukocytes; IFNβ—produced by fibroblasts and epithelial cells) and type 2 (IFNγ—produced 
by activated T cells and NK cells). Viral infection activates pattern recognition receptors 
such as toll-like receptors (TLR) on macrophages and induces early IFN-1 activation. This 
further accelerates viral clearance by the upregulation of adaptive immune response [47]. 
Clinical applications of treatment with exogenous IFN include hematologic malignancies 
such as CML, lymphoma, PV; solid tumors such as renal cell carcinoma; and nonmalignant 
Figure 6. Outcome analysis data: Of the 67 patients with available outcome data, 27 patients (40%) had complete 
response, 28 (42%) developed persistent CKD and 12 (18%) died. Data were shown by underlying diagnosis.
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 disorders such as MS and HCV. Besides CML and one case each of Sezary syndrome and 
hairy cell leukemia, IFN use has not been associated with TMA in any other myeloid or lym-
phoid malignancy [46, 48–52].
In order to understand pathologic process involved, it is important to outline the known 
and proposed mechanisms of action of IFN. Recombinant type I interferons (α and β) are 
pleiotropic cytokines that affect cellular function via immune regulatory mechanisms along 
with the regulation of cellular proliferation, apoptosis and angiogenesis. Dominant mecha-
nisms are also disease specific. For example, in MS, T regulatory cell (Treg) dysregulation 
and decreased T helper (Th1) activity have been associated with clinical relapses [53]. Also, 
more recently, immunopathologic response from Th17 expansion and breakdown of blood 
brain barrier (BBB) have been implicated. Among other mechanisms, recombinant IFNβ is 
thought to restore Th1/Th2 balance, Treg function and regulation of T cell trafficking across 
BBB, thereby decreasing neuronal damage.
IFN action in myeloproliferative neoplasms (MPNs) is more complex, is incompletely under-
stood and appears to utilize several pathways. While IFNα is not a Janus kinase 2 (JAK-2) 
inhibitor, it is able to eliminate the malignant JAK 2 mutant clone and achieve molecular 
remission in PV. There are a few widely accepted hypotheses for the mechanism of action 
of IFNα in MPN: enhanced cycling of quiescent leukemic stem cells (LSCs), restoration of 
dendritic cell function and promoting T cell activation by overcoming T cell energy [54–56].
Several possible pathophysiologic mechanisms have been described by which IFN may 
lead to TMA. In our review, cases with a clear diagnosis of TTP (with measured low levels 
of ADAMTS 13) also had ADAMTS 13 antibodies (ADAMTS 13 inhibitor). It appears that 
IFN-induced immune response plays a pivotal role in the production of cross-reacting anti-
ADAMTS-13 antibodies with resultant microangiopathic hemolysis. While seemingly specu-
lative, this observation has to be seen in the context of association of interferon therapy with 
the development of other autoimmune diseases. Prospective studies from patients treated 
with IFNα for hepatitis C showed that approximately 40% patients developed antithyroid 
antibodies with 15% developing clinical disease [57]. There are three different types of thy-
roid dysfunction associated with the IFN treatment: autoimmune (often subclinical) hypo-
thyroidism, destructive thyroiditis and Graves hyperthyroidism. Females carry a higher 
risk to develop autoimmune thyroid disorders (AITDs) upon IFN treatment, with a relative 
risk of 4.4 (95% CI, 3.2–5.9) [58]. The pattern of thyroid disease observed resembles endog-
enous immunostimulation in the postpartum period. Development of multiple sclerosis has 
also been reported following the treatment of chronic phase CML with IFNα2b [59]. Taken 
together, these observations lend support to our inference that immune activation is funda-
mental for IFN-induced TTP.
The pathogenesis of TMA may also involve inhibition of vascular endothelial growth factor 
(VEGF) in renal podocytes [60]. Under physiologic conditions, VEGF stimulates signal trans-
duction pathways and transcription through activation of its receptor VEGFR2. These events 
are essential for angiogenesis. The physiologic role of VEGF in kidneys is unclear but it has 
been associated with the pathophysiology of various renal diseases. Renal consequences of 
VEGF inhibition have been studied for VEGF antagonist bevacizumab. It has been proposed 
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that local production of VEGF plays a critical protective role in microangiopathic processes. 
VEGF inhibitors such as bevacizumab disrupt this pathway and promote thrombotic micro-
angiopathy [61]. IFN type 1 family also causes VEGF inhibition and hence may have a shared 
pathogenetic mechanism with VEGF antagonists. Vasoconstrictive and pro-coagulant effects 
of type I interferon have also been studied in pulmonary arterial hypertension. Experimental 
models have shown that IFNα increases pulmonary vascular resistance by the activation of 
thromboxane cascade [62].
There are various mechanisms proposed for IFN-induced HUS. Increased leukocyte adhe-
sion to endothelial cells triggers endothelial damage and releases large multimers of von 
Willebrand factor causing endothelial swelling, platelet aggregation and intraluminal micro-
thrombi formation causing tissue injury [63]. The development of antiphospholipid antibod-
ies [64], antiendothelial cell antibodies and overexpression of class I antigens rendering cells 
vulnerable to cytotoxic response are some of the other described mechanisms [65].
Kavanagh et al. described potential immune-mediated and toxic mechanisms of IFN-induced 
TMA in MS patients [66]. They also reported a cumulative dose-toxicity relationship similar 
to our observation. In their analysis of data from a single institution involving eight patients, 
the duration of exposure was similar for IFNα and IFNβ, with TMA developing with long-
term therapy at higher doses. In our analysis of a larger patient cohort, however, there is 
a statistically significant difference between the duration of exposure in MS (treated with 
IFNβ) versus CML and HCV (treated with IFNα). Although there is a complex interplay of 
a multitude of factors, our observations suggest that the underlying disease process is a key 
determinant accounting for the differences in the duration of exposure to IFN preceding onset 
of TMA. Additionally, however, the differences in IFN subtype (due to the differences in 
potencies of immunomodulatory and antiproliferative properties) is probably an additional, 
but secondary factor. In MS, among the accepted underlying mechanisms of IFN action is the 
ability to regain immunologic balance by restoring Treg cell function. On the other hand, in 
CML, IFN treatment creates a proinflammatory state for effective immune surveillance. This 
is supported by the observation of clonal T cell expansion in CML patients treated with IFNα. 
This difference between immune modulation and immune escalation could possibly account 
for the earlier development of TMA in CML. Similarly, in treatment of HCV, exogenous IFN 
binds to cell surface receptors and causes activation of IFN response genes (IRGs) via signal 
transduction through JAK–STAT pathway. This augments inflammatory response creating an 
antiviral state [67]. Immune dysfunction is commonly seen in lymphoproliferative disorders 
wherein the malignant cells originate from the immune system itself. It is therefore possible 
that impaired autoantibody production in this setting may be the reason for the lack of any 
observed cases of TMA in lymphoma. Limited clinical indications for IFN use may explain 
similar finding in PV.
Early diagnosis and prompt institution of treatment is of paramount importance in TMA. In 
contrast to drug-induced thrombocytopenia, IFN-induced TMA is insidious in onset with 
long incubation periods (average 40.2 months) and may masquerade as a more benign con-
dition. It is therefore imperative that this association is recognized in clinical practice. Since 
ADAMTS13 results are not available in real time, a proposed quick guide to determine the 
likelihood of severely deficient ADAMTS13 activity is PLASMIC score (platelets, lysis, active 
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cancer, stem cell or solid organ transplant, MCV, INR, creatinine): 0–4 score is associated with 
a low risk of severe ADAMTS13 deficiency, 5 score with intermediate risk and 6–7 scores with 
high risk [68].
Determining appropriate treatment for drug-associated TMA is challenging. Discontinuation 
of offending medication is the logical first step. Plasma exchange remains the standard treat-
ment for acquired TTP. That said, since antibodies are present in only a small proportion of 
drug-associated TMA, the efficacy of plasma exchange in this setting is unclear [66]. A novel 
upcoming treatment option for patients with acquired TTP is Caplacizumab. This anti-von 
Willebrand factor (vWF) humanized immunoglobulin blocks vWF-mediated plasma aggre-
gation and showed a 67% reduction in recurrence, 74% reduction in TTP-related death and 
a trend toward faster normalization of the three organ damage markers: lactate dehydroge-
nase (LDH), troponin and serum creatinine in the double-blind, placebo-controlled, phase 
3 HERCULES trial [69]. These novel strategies may be a harbinger for new, more effective 
therapeutic options in TTP.
In the past few decades, most of the reported cases of IFN-induced TMA have been associated 
with CML, MS and chronic hepatitis C. Tyrosine kinase inhibitors are now the treatment stan-
dard for CML. Therefore, not surprisingly, there have been no reports of IFN-induced TMA 
in patients with CML in the last decade. In addition, with the development of more effective 
antiviral agents, interferon-free regimens for chronic hepatitis C are emerging. Taken together, 
with diminishing clinical applications of IFN, we may see an overall decrease in the reports 
of IFN-induced TMA hereon. The last few years, however, have also seen the emergence of 
immunooncology in cancer therapeutics. Immune checkpoint inhibitors including CTLA-4 
antibodies and PD-1 ligands are now approved with expanding clinical applications. These 
agents potentiate immune response against tumors exponentially by blocking the inhibitory 
pathways utilized by tumors to escape host immune surveillance mechanisms. Augmentation 
of host immunity, however, results in breaking self-tolerance and induction of immune-related 
side effects (ir-AE). Most common side effects are colitis and pneumonitis requiring immune 
suppression for resolution. Cortazar et al. described a 58-year-old male with melanoma who 
developed TMA that correlated with treatment with Ipilimumab (CTLA-4 antibody) [70]. 
This is an interesting observation in the context of our analysis, especially of the mechanisms 
involved in IFN-induced TMA. It is yet to be ascertained, as we gain more experience with 
these agents whether this will be an isolated or consistent observation. Nevertheless, it would 
be prudent to consider the likelihood of these adverse effects in the future.
4. Conclusion
Historically, exogenous IFN (α and β) has been the primary therapy for a variety of diseases 
such as chronic HCV, chronic phase CML, MS, lymphoma and PV. IFN can trigger autoim-
mune diseases such as autoimmune thyroiditis. IFN-mediated immune upregulation with 
the production of cross-reacting antibodies to ADAMTS 13 and complement activation from 
endothelial injury are the probable pathways for IFN-induced TMA. From our observation, 
barring differences in time of onset and cumulative dose exposure, the presentation, clinical 
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course and response to treatment appear to be similar among different IFN subtypes and 
across all indications of use. Treatment regimens utilizing plasma exchange, steroids and 
rituximab result in durable responses. While interferon may have a myelosuppressive effect 
causing gradual onset thrombocytopenia, thrombotic microangiopathy, a possible fatal com-
plication should be considered in the differential diagnosis. Once recognized, early institu-
tion of appropriate treatment results in favorable outcome. Our analysis also indicates that 
in patients who had positive ADAMTS13 inhibitors, plasma exchange was a very effective 
therapy with complete response. Finally, while interferons may have diminishing clinical 
applications, interferon-induced thrombotic microangiopathy has provided us with valuable 
lessons pertaining to collateral consequences of immune upregulation. This has resulted in a 
paradigm shift in our understanding of immunobiology and will have far reaching applica-
tions in immunomodulating therapeutics.
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